<DOC>
	<DOC>NCT00242333</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD</brief_title>
	<detailed_description />
	<criteria>Diagnosed with COPD, with symptoms of cough and chronic sputum production and/or dyspnea. Postbronchodilator FEV1 at no more than 65% and at least 30% of the predicted normal value. Prebronchodilator FEV1/FVC ratio of less than 70%. Current or exsmokers with a smoking history of at least 10 pack years. History of asthma, atopy or allergic rhinitis. Other serious respiratory or other medical conditions which may interfere with the outcome of the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>COPD</keyword>
	<keyword>COAD</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>emphysema</keyword>
	<keyword>chronic bronchitis</keyword>
</DOC>